Unexpectedly, both CD8<sup>+</sup> T cells and NK cells, but not CD4<sup>+</sup> T cells, were required for the efficacy of CD40 agonist, even though CD8<sup>+</sup> T cells cannot directly recognize antigen presentation-deficient tumor cells. This evidence concerns the gene CD8A and neoplasm.